Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Shares of Moderna Inc. fell sharply on Monday after the biotech firm projected a steep decline in 2025 revenues, falling below Wall Street expectations. The company, known for its COVID-19 vaccine ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Drug maker Moderna's stock plunged more than 17% in pre-market trading on Monday after the company slashed its sales outlook by $1 billion. The company reported product sales of $3 to $3.1 billion ...

(Bloomberg) -- Moderna Inc. was awarded an additional $590 million from the US government to help the company develop a vaccine aimed at protecting people from bird flu.Most Read from ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images) The stock price of Moderna saw a 12% jump on ...

Meta Platforms is ending fact-checking and speech restrictions across Facebook and Instagram, as Chief Executive Mark Zuckerberg embraces a second Trump presidency. Starting in the U.S., Meta will ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...